Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=82 SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Parkinson's Disease Dementia (PDD)
Primary: The Primary Efficacy Objective of This Study is to Assess the Efficacy of SYN120 on Cognition as Determined by the Cognitive Drug Research Computerized Cognition Battery…
Phase 3 N=583 Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
Parkinson's Disease Dementia
Primary: Percentage of Participants With Adverse Events (AEs) Due, or Potentially Due, to Worsening of Parkinson Disease (PD) Motor Symptoms (Tremor, Muscle Rigidity…
N/A N=5,325 Digital Detection of Dementia (D Cubed) Studies: D2
Alzheimer Disease and Related Dementias (ADRD)
Primary: 12-Month Cumulative Incidence of ADRD Diagnoses — 213; 134; 355 Number of new ADRD cases — p=0.006
Phase 4 N=28 Mild Cognitive Impairment in Parkinson's Disease
Parkinson's Disease · Mild Cognitive Impairment
Primary: Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC) — 3.92; 3.48 scores on the CGIC
N/A N=20 Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia
Parkinson's Disease · Cognitive Impairment · Dementia
Primary: Change in Dementia Rating Scale (DRS) Memory Subscore — 1.6; -1.4 units on a scale
Phase 2 N=344 A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Lewy Body Dementia
Primary: Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) — 1.04; 0.15; 0.96…
Phase 2 N=34 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Dementia With Lewy Bodies · REM Sleep Behavior Disorder · Parkinson's Disease Dementia
Primary: Change in the Frequency of REM Sleep Behavior Disorders (RBD) From Baseline to the End of the Treatment Period (28 Days) Based on a Clinical Evaluator. — -1.47; -0.26…
Phase 4 N=296 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinson Disease · Depression
Primary: Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12 — -4; -5.9 Score on scale — p=0.0103
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
Phase 2 N=34 A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
Lewy Body Disease · Parkinson Disease
Primary: Percent Change From Baseline in Cerebrospinal Fluid (CSF) Cyclic Guanosine Monophosphate (cGMP) at Week 9 — 230.412; 250.434; 186.869; 362.519 Percent Change in CSF…
Phase 2 N=5 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Diffuse Lewy Body Disease · Dementia With Lewy Bodies · Parkinson's Disease Dementia
Primary: Absolute 11C-PBR28 Binding (Total Distribution Volume Corrected for Free Fraction in Plasma) — 0.15 kBq·cm-3 / kBq·mL-1
Phase 3 N=199 A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Parkinson's Disease Psychosis
Primary: Antipsychotic Efficacy — -2.73; -5.79; NA; -3.06 Score on the SAPS-PD scale
Phase 2 N=39 An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Parkinson's Disease Psychosis
Primary: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) — 17 Participants
Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
Phase 3 N=30 Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
N/A N=49 Cognitive Dysfunction in Parkinson's Disease
Parkinson's Disease
Primary: Change in Magnetoencephalography (MEG) Connectivity Measures
N/A N=9 Effect of Exercise in Parkinsonism
Parkinson's Disease · Drug-induced Parkinsonism
Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=57 Aerobic Exercise in Parkinson's Disease
Parkinson's Disease
Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05
Phase 4 N=29 Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
Parkinson Disease Psychosis
Primary: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score — 14.0 score on a scale — p=<0.0001
Phase 2 N=68 Effects of Vitamin D in Parkinson's Disease (PD)
Parkinson Disease · Accidental Falls
Primary: Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3) — -3.25; 2.05; 1.78 units on a scale — p=0.699
Phase 4 N=9 Cognitive Decline in Non-demented PD
Parkinson's Disease
Primary: Attention Network Effects
Phase 2 N=22 A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants
Phase 3 N=778 A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
Parkinson Disease
Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700
Phase 2 N=253 Dyskinesia in Parkinson's Disease (Study P04501)
Parkinson Disease · Movement Disorders · Central Nervous System Diseases
Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753
Phase 4 N=535 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
Parkinson Disease
Primary: Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15 — 0.3; 0.7 Units on a scale — p=0.6503
N/A N=37 Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Parkinson's Disease
Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468
N/A N=110 Cognitive Rehabilitation for PD
Parkinson's Disease
Primary: Wechsler Adult Intelligence Scale-IV (WAIS-IV) Matrix Reasoning Test Total Scaled Score — 0.22; 0.42 score on a scale — p=0.6662
Phase 2 N=31 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
Parkinson's Disease
Primary: Mean Cortical Amyloid Burden — 0.990; 1.051; 1.146 SUVR